Metformin in Non-Diabetics: Risks, Off-Label Uses, and Evidence Gaps

Standard Indication

Metformin is FDA-approved for type 2 diabetes (adjunct to diet/exercise). It lowers hepatic gluconeogenesis, increases insulin sensitivity, and modestly reduces intestinal glucose absorption.

Why Not for Non-Diabetics?

  • Hypoglycemia risk: Rare with monotherapy (no insulin secretion ↑), but possible with malnutrition, alcohol, renal impairment, or combined with other glucose-lowering agents.
  • GI adverse effects: Diarrhea, nausea, abdominal pain in 20–30% (dose-dependent).
  • B12 deficiency: Long-term use ↓ intrinsic factor-mediated absorption.
  • Lactic acidosis: Rare (3–10/100,000 patient-years) but fatal; contraindicated in eGFR <30, acute heart failure, hypoxia, sepsis.

Evidence-Based Off-Label Uses

ConditionEvidence StrengthNotes
PCOS (ovulation induction)ModerateAdjunct to letrozole/clomiphene; improves insulin resistance
Antipsychotic-induced weight gainModerateAttenuates gain; monitor B12
Gestational DiabetesStrong (RCTs)Alternative to insulin in selected patients
Cancer prevention (breast, colon)Observational onlyRCTs ongoing (MA.32, METFORMIN)
Aging / LongevityPreclinical / observationalTAME trial planned; not standard of care

Clinical Bottom Line

Do not initiate metformin without a diagnosed indication. If prescribed off-label, ensure informed consent, baseline labs (eGFR, B12, LFTs), and monitoring plan.

Diabetes - Related Articles